Whittier Trust Co. of Nevada Inc. raised its position in Danaher Co. (NYSE:DHR - Free Report) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,281 shares of the conglomerate's stock after purchasing an additional 2,397 shares during the quarter. Whittier Trust Co. of Nevada Inc.'s holdings in Danaher were worth $14,296,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in DHR. FMR LLC lifted its stake in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock worth $1,971,609,000 after purchasing an additional 441,012 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock worth $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Danaher by 0.6% during the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate's stock valued at $1,051,097,000 after purchasing an additional 26,305 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Danaher by 3.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock worth $933,524,000 after purchasing an additional 135,047 shares during the last quarter. Institutional investors own 79.05% of the company's stock.
Analyst Ratings Changes
DHR has been the subject of a number of research analyst reports. Barclays decreased their price objective on shares of Danaher from $275.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. JPMorgan Chase & Co. decreased their price target on shares of Danaher from $310.00 to $300.00 and set an "overweight" rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company dropped their price objective on Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. The Goldman Sachs Group upgraded Danaher from a "neutral" rating to a "buy" rating and set a $260.00 price objective on the stock in a report on Friday. Finally, Raymond James reiterated a "market perform" rating on shares of Danaher in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $278.24.
Read Our Latest Research Report on DHR
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 11.10% of the company's stock.
Danaher Trading Down 0.2 %
Shares of NYSE:DHR traded down $0.44 during midday trading on Tuesday, reaching $212.36. 3,077,187 shares of the company's stock were exchanged, compared to its average volume of 3,016,116. The stock has a market cap of $151.78 billion, a price-to-earnings ratio of 40.22, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The firm's 50 day simple moving average is $216.92 and its two-hundred day simple moving average is $238.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts' consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. This is a boost from Danaher's previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher's dividend payout ratio is 24.24%.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
